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The aim of our study was to quantitatively assess the 
impact of hepatic retransplantation on patient and graft 
survival and resource utilization. We studied patients 
undergOing hepatic retransplantation among 447 transplant 
recipients with primary biliary cirrhosis (PBC) and primary 
sclerosing cholangitis (PSC) at 3 transplantation centers. 
Cox proportional hazards regression analysis was used for 
survival analysis. Measures of resource utilization included 
the duration of hospitalization, length of stay in the 
intensive care unit, and the duration of transplantation 
surgery. Forty-six 00.3%) patients received 2 or more grafts 
during the follow-up period (median, 2.8 years). Patients 
who underwent retransplantation had a 3.8-fold increase in 
the risk of death compared with those without retransplan-
tation (P < .01). Retransplantation after an interval of 
greater than 30 days from the primary graft was associated 
with a 6.7 -fold increase in the risk of death (P < .01). The 
survival following retransplantations performed 30 days or 
earlier was similar to primary transplantations. Resource 
utilization was higher in patients who underwent multiple 
consecutive transplantations, even after adjustment for the 
number of grafts during the hospitalization. Among chole-
static liver disease patients, poor survival following hepatic 
retransplantation is attributed to late retransplantations, 
namely those performed more than 30 days after the initial 
transplantation. While efforts must be made to improve the 
outcome following retransplantation, a more critical evalua-
tion may be warranted for late retransplantation candi-
dates. (HEPATOLOGY 1999;30:395-400.) 
Despite recent progress in liver transplantation, a gap 
remains between the patient and graft survival rates, under-
scoring a continued need for retransplantation.' For many 
patients with initial graft failure, retransplantation consti-
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tutes the only alternative to death. 2 At this time, over 10% of 
all donor organs are being used for retransplantation.3 
Retransplantation is a difficult clinical dilemma. First, 
retransplantation is associated with a lower survival. Patients 
who receive retransplantation have a survival that is consis-
tently 20 percentage points or more below that of primary 
transplant recipients, a difference apparent as early as 3 
months' posttransplantation.3 Second, given the severe short-
age of organs available for transplantation. there is an ethical 
question of equity in the distribution of these scarce re-
sources.45 During 1996. 923 patients died while awaiting a 
liver, while 422 patients received retransplants. 3 Finally, 
retransplantation is known to be more expensive. The 
charges incurred for evaluation, transplantation, and 6 months 
of postoperative care of patients who had retransplantation 
were found to be more than twice that of patients with a 
single graft. 6 
To derive a rational strategy for organ distribution, as well 
as optimal patient management. the transplantation commu-
nity must better understand the pathophysiology, risk factors, 
and determinants of outcome of hepatic retransplantation. 
Therefore, this analysis was undertaken with 3 objectives in 
mind: 1) to quantitatively assess the impact of retransplanta-
tion on survival in patients with primary biliary cirrhosis 
(PBC) and primary scleroSing cholangitiS (PSC); 2) to 
identify risk factors or patient subgroups that may be 
particularly responsible for the poor prognosiS associated 
with retransplantation; and 3) to compare resource utilization 
between primary and retransplantation. 
PATIENTS AND METHODS 
Patient 5election and Management. We prospectively collected data 
in 448 patients with PBC and PSC undergOing liver transplantation 
at 3 transplantation centers (Baylor University Medical Center, 
Mayo Clinic, and University of Pittsburgh). The overall goal of the 
study was to systematically analyze the outcome of liver transplanta-
tion in patients with cholestatic liver disease. The study was 
approved by the Institutional Review Board of each of the contribut-
ing centers. A complete pre transplantation evaluation had been 
conducted to verify the diagnosis in each patient. FollOwing 
transplantation. patients were followed regularly. with clinical 
examination and laboratory tests. including liver biochemistry. drug 
levels. and graft biopSies. Individual patient management. including 
the immunosuppressive regimen and decisions for retransplanta-
tion. was conducted by transplantation physicians at each institu-
tion. Our patient population has been described in detail previ-
ously.' 
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Data Collection and Statistical Analysis. Information, including pre-
transplantatIon patient characteristics. intra- and postoperative 
events, and posttransplantation follow-up, was prospectively col-
lected for each patient. The National Institute of Diabetes, Digestive 
and Kidney Diseases-Liver Transplant Database (NlDDK-LTD) 
forms were used for data collection. These data were entered at each 
center and transmitted electronically to the Mayo Clinic data 
coordinating center. All data management and analysis was under-
taken using the SAS package (SAS Institute, Cary, NC). 
Comparison of survival between groups was performed by Cox 
proportional hazards regression analysis. Graft survival was defined 
as the time that elapsed from each transplantation until graft failure, 
patient death, or last follow-up. In the analysis of graft survival, 
survival of each graft, including retransplants, was individually 
assessed. Patient SUrvival was assessed by the interval between the 
first transplantation and patient's death or last follow-up. Propor-
tional hazards analysis for patient survival was conducted treating 
retransplantation as a time-dependent cQvariate. This method is 
considered most appropriate in assessing the impact on patient 
survival of variables that occur after a given treatment. In this case, 
the treatment at time zero was the first transplantation and the 
variable being evaluated was retransplantation.8 Thus, on the one 
hand, our analysis of graft SUrvival addresses the following question: 
what is the likelihood for graft failure when a given organ is used for 
a retransplant as compared with a primarv transplant? On the other 
hand, our analysis of patient survival compares the sUfVlval of 
individuals who later required retransplantation with those who did 
not, as assessed from the time of first transplantation. 
Resource utilization was measured in terms of the duration of the 
transplantation procedure, the number of days in the intensive care 
units (lCU), and the tatallength of hospitalization, all of which have 
been shown to highly correlate with overall resource utilization.9 
The length-oC-stay parameters were counted from the day of 
transplantation. In light of the skewed distribution of these vari-
ables, the rank sum test was employed for group comparisons. 
Two-tailed P values are reported with the traditional cut-off of 0.05. 
RESULTS 
Description of Patient Population. Pre transplantation patient 
characteristics are summarized in Table 1. Of the "f48 
patients, 1 had missing data on retransplantation and was 
therefore excluded from the analvsis. Patients were almost 
equally divided between PBC and Psc. Approximately two 
thirds were female. When the Mayo risk scores were used as a 
measure of disease severity, patients at all 3 centers were 
comparable in both diagnoses. lo.11 Although the data collec-
tion spanned over a decade, most of the transplantations were 
performed since 1990, leading to a median length of fol-
low-up of 2.8 years (range, 0.1-10.0 years). 
Overall, 500 grafts were used for the 447 patients, 46 of 
whom (10.3%) received 2 or more grafts. Forty patients had 2 
TABLE l. Pretransplant Patient Characteristics and Survival 
Center I Center 2 Center 3 
Center tn = 205) tn = t06) (n = 136) 
PBGPSC 115/90 -+l/64 771S9 
.-\ge< 4'1.3 ~ 10.4 50.2 ~ 10.2 52,9 ~ 12.3 
Sex ('Yo femalcl 71.6 M.2 6S.9 
\lavo Risk score' 
PBC 7.33 :!: 1.-l8 7.76::: 1.31 7.38::: 1.-+2 
PSC 5.20 :!: 0.77 5.31 :!: l).Y3 4.44 :!: 0.92 
a~tcs 01 l)L T -l/8S-SNS -lNO--lN4 tl/90-IN5 
Deaths 36 () 12 
\bbrcVI,llIon: llLT. (lrthOIOPIC liver Iranspiallt3non. 
"!can ::: ~aK 
Total 
tn = .... 7) 
234/213 
50.6 ~ Il.l 
68.1 
7.-+3 :!: I.H 
5.16 ~ ll.88 
-l/8S·INS 
54 
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grafts, 5 received 3, and 1 patient reqUired 4 grafts, while 401 
patients did not require a retransplant. The retransplantation 
rate between 1985 and 1989 was 19.8%. Since 1990, however, 
the retransplantation rate has decreased to 8.2%, which was 
similar at all 3 centers (7.3%,8.1%, and 9.4%; P = .55). 
Survival Following Retransplantation. Figure lA compares the 
graft survival rates for primary transplants and retransplants. 
Liver grafts used for retransplantation had clearly shorter 
survival than those used for primary transplants. Figure 1B 
demonstrates that the survival of patients who received 
retransplantation was shorter despite the usage of multiple 
grafts. The Cox model indicates that the relative risk of death 
is 3.8 times greater (95% confidence interval: 2.0-8.0; P < 
.00 in patients who had retransplants than those who had' 
only primary graft. This difference was independent of the era 
of transplantation: when patients since 1990 only were 
considered, the relative risk decreased slightly to 2.7 (95% 
confidence interval: 1.1-7.2; P = .04), 
Interval to Retransplantation. We next examined the influ-
ence of the interval to retransplantation on the survival 
outcome. The interval had a skewed distribution (median, 84 
days; range, 1-1,441 days). We chose 30 days as a cut-off 
criterion and compared graft and patient survival between the 
early (::::30 days) and late (>30 days) retransplants. In the 6 
patients who had more than 1 retransplant, the classification 
was based on the interval to the first retransplant. The 
interval from the primary graft to early retransplants (median 
[rangeD was 4 (1-29) days, and to late retransplants, it was 
150.5 06-1,441) days. 
In Fig. 2A, graft survival between the early and late 
retransplant groups is compared. The late retransplants were 
3.0 times more likely to fail than primary transplants (95% 
confidence interval: l.7-5.3; P < .01). Survival of early 
retransplants was not statistically different from that of the 
primary transplants (relative risk = 0.8; 95% confidence 
interval: 0.3-2.3). 
Figure 2B clearly shows the difference in patient survival 
between the early and late retransplant groups. The late 
retransplant group had a significantly lower survival with a 
relative risk of death of 6.7 (P < .01) compared with the 
primary transplant group (95% confidence interval: 3.3-
13.6). Survival in patients in the early retransplant group was 
not different from the primary transplant group (relative 
risk = 1.2 [P = .821; 95% confidence interval: 0.3-4.9). The 
survival difference between the late retransplant and primary 
transplant groups persisted when patients transplanted since 
1990 only were considered (relative risk = 4.6 (P < .011; 95% 
confidence interval: l.6-13.6). 
Early Versus Late Retransplants. Table 2 describes the reasons 
for retransplantation (first retransplantation in patients with 
more than 2 transplants) in the early and late retransplant 
groups. More than half of the early retransplants were the 
result of primarv nonfunction, whereas late retransplantation 
was mostly performed for rejection and biliary complications. 
Thus, the reason for graft failure may underlie the difference 
in the outcome of early and late retransplants. Unfortunately, 
the small number of patients in each of these categories 
precluded a meaningful analysis to separate out such effects. 
Nine of the III pnmarv nonfuncl1ons were since 1990, 
~uggesting that with the recent donor shortage, transplant 
centers mav be willing to accept more marginal organs. 
We also cOl1slticreu the 5everitv of hepatic dysfunction 
hefore rctranspianlatlOll as a pOSSible explanation for the 
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FIG. 1. Survival (Kaplan-Meier estimates) followmg hepatic rctransplan-
tallon. (A) Comparison of graft survIval evaluating each graft individually. 
(8) Companson of patient survival as assessed from the time of initial 
transplantation. Patients and grafts in the retransplantation group had a 
significantly shorter survival than those who did not have retransplants (P < 
III ). 
difference of outcome between early and late retransplants 
(Table 3). The early retransplant group had more severe liver 
dysfunction at the time of retransplantation as indicated by 
biochemical parameters and functional status. Thus, the 
worse outcome in the late retransplant group could not be 
attributed to their preoperative condition. 
Table 4 lists the primary cause of death as reported by the 
centers for each group of patients. The proportion of deaths 
from hepatic failure and intraoperative deaths appeared 
higher in the late retransplant group than the other 2 groups, 
although this difference mayor may not be significant, given 
the subjective inHuence in assigning causes of death in a 
population in which simultaneous multiorgan failure is 
frequent. Of the 6 patients who had more than 1 retransplant, 
+ died within 1 year of the last retransplantauon. 
Resourcc Utilization Associated With Rctransplanuuion. As noted 
previously, we used 3 indicators of resource utilization 
including the duration of the transplantation procedure. the 
number of davs in the ICU, and total length of hospitaliza-
tion. The duration of the transplantation procedure was 
compared between the early and late retransplantatlons. Un 
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FIG. 2. Graft (A) and patient (B) survival follOwing early «30 days) and 
late (;;::30 days) hepatic retransplantation. Late retransplants had a signifi-
cantly shoner survival than primary grafts or early retransplants (P <01). 
average, late retransplantation performed more than 30 days 
after initial transplantation took 2,4 hours longer than early 
retransplantation, after adjusting for the institution (P < 
.0l).The length-of-stay data are summarized in Table 5. The 
500 transplantations occurred during 478 hospitalizations. 
Of these, 428 hospitalizations were for a Single primary 
transplant, and 29 were for a single retransplant. In the 
remaining 21 hospitalizations, 2 or more transplantations 
occurred during 1 stay. Of these 21 hospitalizations with 
multiple transplants. 14 (67%) included early retransplants 
within 30 days of the primary transplantation. In contrast, 25 
TABLE 2. Reasons for First Retransplantation 
Early Lale 
Retransplants Retransplants 
Reason (S30d) (>30d) Total 
Primary nonfUnCtlLln 10 10 (22%) 
RejectlLln 5 12 17 (37%) 
Hepatic arterv thrombOSIS I -+(9%) 
Biliar.· stncturclcholangllls 2 7 <) (19%) 
\ )ther (Unknown J b (5) b (\3%) 
r,lIal IR 28 -+h (100%) 
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TABLE 3. Indicators of the Severity of Hepatic Dysfunction Before Primary 
Transplantation and Retransplantation 
Primary Early Late 
Transplants Retransplants Retransplants 
(N = 447) (N = 19) (N = 34) p"" 
50.6:': ILl 52.0 :': 10.0 45.3:': 9.2 .04 Age 
Bilirubin 9.2:': 9.7 14.8 :': 14.6 14.8:': 11.9 .9 
Albumin 3.2:': 0.7 2.7:': 0.7 4.3:': 4.8 <.01 
Prothrombin time 13.7 :': 2.1 20.9 :': 8.9 13.9 :': 4.2 <.01 
Aspartate transammase 193 :': 323 2403:': 3542 406:': 852 <.01 
Alkaline phosphatase 782:': 690 349:': 270 1202:': 1255 <'01 
Creatinine 1.1 :': 0.8 1.4:': 0.9 1.4:': 0.7 .8 
Karnofsky scoret 56.6:': 21.6 22.1 :': 21.0 50.7:': 27.1 <.01 
*Companson between the early and late groups (Wilcoxon).. . 
tDefinition of the Karnofsky score: 100: normal; 90: mmor sIgns or 
symptoms of disease. but able to carry on normal activity; 80: some signs or 
symptoms of disease. Normal activity with effort; 70: cares for self but unable 
to carry on normal activity; 60: requires occasional assIstance but IS able to 
care for most of own needs; 50: requires considerable assistance and frequent 
medical care; 40: disabled. Requires special care and assistance; 30: severely 
disabled. Hospitalization is indicated. although death is not imminent; 20: 
active supportive treatment is necessary to sustain life; 10: moribund. fatal 
processes progressing rapidly. 
(86%) of the 29 hospitalizations for single retransplants were 
late retransplants. 
In Table 5. the length of stay for a Single retransplant was 
similar to those for a single primary transplant. In contrast, 
the length of hospitalization was Significantly longer 10 
patients who received multiple transplants dunng 1 hospital-
ization as compared with those who underwent a s10gle 
primary or retransplant. Of note. data in patients who 
received multiple transplants during a continuous hospuahza-
tion are presented on a per-graft basis. For example, the 
length of stay in hospital was divided by the number of 
transplants. because these patients were essentially recover-
ing from 2 or more consecutive transplants. Similarly. the 
duration of lCU stay was longer in the multiple-transplant 
group. although the difference did not reach statistical 
Significance. We also considered the number of 1O-hosp.nal 
deaths for each group, because the duration of hospuahza-
tion. particularly for the retransplant groups, could have been 
spuriously shortened by early deaths. Although the propor-
tion of in-hospital deaths was, indeed. higher in the retrans-
plant groups, these few deaths did not have a significant effect 
on the overall length of stay. 
Causes" 
I kpall, ladure 
I nfectlOnimultiorgan 
bdure wnhout 
hepallc faHur.: 
Illtraabdommal «'m-
plicallons 
\lalignanclcs 
Intraopcratlve 
( lther \ unknown t 
TABLE 4. Causes of Death 
Primary Early late 
Transplantation Retransplantation Retransplantation 
(n=411 (n=2l (n=l\) 
5 
2 
i 
-HI) 1 (\) 
·11 = number 01 deaths. 
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TABLE 5. Length of Stay in Hospital and ICU 
Single 
Single Multiple Primary 
Transplant Retransplant* Transplantst 
(n = 428) (n = 29) (n = 21) P 
Length of stay in 
hospital (dH 17 (13-28) 17 (13-25) 28§ 02-47) .05 
Length of stay m 
ICU (dH 3 (2-6) 3 (2-6) 5.75§ (2.75-16) .12 
In-hospital 
death (%) 14 (3.3%) 3 (103%) 2 (95%) .05 
*Retransplantation followed by a successful dismissal from the hospital. 
tMore than one transplant given during one hospitalization. 
~Median (interquartile range) in days. 
§Total duration (in days)/number of grafts. 
DISCUSSION 
Lower survival in patients undergoing retransplantation 
has been well documented. According to a report from the 
UNOS, the 3-year survival rate in patients who had retrans-
plants was 53.7%, as compared with 77.4% in primary 
transplant recipients. 3 In our series, we observed that the 
difference in survival still exists in patients who otherwise 
have the most favorable outcome after liver transplantation. 
namely those with PBC and PSc. Retransplantation was 
associated with almost a 4-fold increase in the risk of death. 
Fortunately, with the advent of more potent immunosuppres-
sants, improved donor organ selection, and better organ 
preservation in the last decade, the retransplantation rate has 
been substantially reduced •. as has been confirmed in this 
report. 12-14 
The pathophysiological mechanism underlying the lower 
survival rate associated with retransplantation remains to be 
defined, although multiorgan dysfunction associated with 
failing grafts is likely to contribute to a high perioperative 
mortality.15,l6 Our data suggest that at least in patients with 
cholestatic liver disease. the poor outcome of retransplanta-
tion may be attributed to late retransplantation performed 
more than 30 days after the first transplantation. We believe 
there are several explanations for the differences in outcome 
between early and late retransplantation. 
First, primary nonfunction, which accounted for more 
than one half of the early retransplants, is most likely to be 
related to donor factors, rather than recipient characteris-
tics. 17 Therefore, replacing the defective graft should result in 
outcomes similar to patients who had a functional graft in the 
first place, provided that retransplantation is performed in a 
timely fashion. III Second, early retransplantation performed 
shortly after the primary transplantation is likely to be easier 
technicallv than late retransplants. where fibrosis surround-
ing the g~aft and blood vessels renders surgery more diffi-
cult. l9 In our patients, the operative time for late retrans-
plants was Significantly longer than early retransplants. Late 
retransplants have also been reported to require more blood 
transfusion than early retransplants. 2 Third. factors specific 
to recipient disease may playa role. Cholestatic liver disease 
patients tend to be relativelv stable at initial transplantation, 
which may enable them to retain more physical reserve to 
withstand the stress associated wllh early retransplants. 
Alternative\\'. the immunologiC basis of the diseases may 
predispose ~ert:lln recipients to experience graft loss repeal~ 
edlv. resulting 111 poor lllltcome after late retransplants.-u 
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Finally, patients with late retransplantation have been subject 
to immunosuppression longer than early retransplant recipi-
ents, Long-term immunosuppression is likely to have an 
adverse impact on the outcome of retransplantation, in terms 
of infectious, renal, and metabolic complications, 
So far, few studies have examined the interval between the 
first and subsequent grafts, Powelson reported that patients 
who received retransplantation 4 to 30 days after the initial 
transplantation had the worst outcome as compared with 
those with shorter or longer intervals, 5 The authors attributed 
the poor outcome in early retransplant recipients to infec-
tious complications and multiple-organ failure follOWing the 
initial transplantation. Another report indicated that the risk 
of graft failure increased linearly to reach a peak between 30 
and 50 days from the previous transplant. 21 It was suggested 
that procrastinating retransplantation in the setting of failing 
graft accounts for the progreSSive inerease in the risk of death. 
We would like to remind the reader that our results must 
be interpreted within the context that this was an observa-
tional study, In particular, an implicit selection of patients for 
retransplantation is embedded in our data, because the 
decision to perform retransplantation in patients with failing 
first graft was made by individual transplant physicians and 
surgeons. ObViously, not all patients with failing graft re-
ceived retransplantation (Table 4). Thus, for example, early 
retransplantation does not guarantee uniformly good out-
comes in all patients with failing graft within 30 days of initial 
transplantation. In this regard, the timing for the first 
transplantation may also be important in the outcome of 
retransplantation. Because the need for early retransplants is 
mostly determined by factors extraneous to the recipient, it 
would be better to have a margin of error in the recipient's 
physical reserve, should a need for retransplantation arise. 
Fortunately, in our patient population of PBC and PSC, the 
natural history of disease progression has been well character-
ized, making it possible to predict patient survival. lO ·11 Such 
consideration is particularly relevant at a time when the 
median waiting time for transplantation exceeds well over 1 
year, 
Our analysis was also limited by the extent of information 
recorded in the database, although our data were prospec-
tively collected on a relativelv large number of patients (n = 
447). Some variables had missing data, while there was not 
sufficiently detailed information to study specific subgroups 
of patients. For example, we were not able to elucidate the 
underlying physiological process that determines the out-
come of retransplantation. We did exclude the preoperative 
morbidity level as the reason for the difference in outcome 
between the early and late retransplant groups. 
Although we speculate that the length of the waiting period 
for retransplantation is an important factor in determining 
the outcome of retransplantation. particularly earlv in the 
posttransplantation period, our database did not include the 
waitmg lime for retransplantation to address the question. 
Nonetheless, we believe the ability to predict the failure of the 
graft earlv in the course is critically important. c22J A timel" 
clinical assessment of the long-term \·iabilit\· of the existing 
graft and a prompt decision for retransplantallon mav prevent 
potentially life-threatening complications and improve the 
eventual outcome. Unfortunatelv. llur ability tll perform 
retransplantation in the most tim~lyD manner lslimiteo bv the 
~evere donor organ shortage and long walling tllne. \\ore-
lwer, the current defintlions of the U;"\lOS statuses IS based on 
KIM ET AL. 399 
the Child-Pugh score for patients awaiting retransplantation 
as well as primary transplanatation, which may put retrans-
plant candidates at a disadvantage. The degree of graft 
dysfunction may not be accurately measured by the Child-
Pugh score, because ascites or severe hepatic synthetic 
dysfunction may not appear until a very late stage. 
From an economic standpoint, retransplantation has been 
regarded as an inappropriate use of scarce resources.;,24 In 
this analYSiS, we discovered that the length of hospitalization 
and ICU stay for a single retransplantation was not different 
from that of primary transplants. In contrast, patients who 
underwent multiple transplants consecutively had a signifi-
cantly longer stay even after adjustment for the number of 
transplants performed during the hospitalization. Many of 
these patients were early retransplant recipients. In light of 
the favorable long-term outcome, however, we believe that 
early retransplantation may be justified, despite higher re-
source utilization. Perhaps early retransplants should be 
viewed as an extension of the first transplant similar to other 
postsurgical morbidities. Then, the additional resource require-
ment induding the donor organs for early retransplants may 
be supported in the same context. Moreover, the length of 
stay following early retransplantation may be shortened by 
timing the retransplant in such a way that multisystem 
dysfunction can be minimized before and after the second 
transplantation. 
In summary, although retransplantation has decreased by 
more than 50% since 1990, patients who receive retransplan-
tation still have significantly lower survival. In our sample of 
liver transplant recipients with PBC and PSC, those who 
undergo late retransplantation are largely responsible for the 
poor outcome of retransplantation. Resource utilization is 
particularly high in patients undergOing multiple transplants 
consecutively. We conclude that given the good long-term 
results, early retransplants should not be discouraged, whereas 
a more careful selection is required for late retransplant 
candidates. In-depth investigation is needed to understand 
factors leading to poor outcome following late retransplants 
and, more importantly, how to avoid them. 
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